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Microsatellite instability may predict response to sipuleucel-T in patients with prostate 
cancer 
 
Kevin Zhang, MD, Bryan P Schneider, MD. Costantine Albany, MD.  
 
 
Clinical Practice Points 
There is currently no data or findings in the literature in regards to microsatellite 
instability high (MSI-H) metastatic castrate-resistant prostate cancer (mCRPC) and their 
response to cell-based immunotherapy such as sipuleucel-T. Our case describes a man 
with MSI-H mCRPC with a complete response to sipuleucel-T. This raises a clinically 
significant question of whether MSI status can predict patient’s response to sipuleucel-T 
and what role whole genome sequencing plays in the management of prostate cancer.  
 
Introduction 
Microsatellite instability (MSI) is a mutational error in repetitive DNA sequences that is 
typically corrected by a DNA mismatch repair system. A failure in this system leads to 
defective mismatch repair (dMMR). The presence of MSI varies amongst different 
cancers, being present in up to 15-20% of colorectal cancers.i Recent data shows that 
2.4% of prostate cancers are MSI-Hii and up to 8.1% show evidence of dMMR.iii 
Currently, pembrolizumab, an immunotherapy-based PDI-1 inhibitor, is approved for 
any MSI-H/dMMR cancer. MSI-H tumors may have higher tumor mutational burden and 
produce a number of neoantigens that trigger the recruitment of tumor-infiltrating 
lymphocytes. As a result of this, these MSI-H tumors strongly express immune 
checkpoints ligands, such as PD-1, to promote immune evasion.iv  
 
Sipuleucel-T is an autologous immunotherapeutic vaccine approved in 2010 for the 
treatment of mCRPC that involves activating the patient’s own dendritic cells, which are 
isolated via leukapheresis. These are exposed to a fusion protein, PA2024, consisting 
of antigen prostatic acid phosphatase (PAP) and GM-CSF. After allowing the incubation 
to mature, the blood product is reintroduced to the patient over the course of three 
treatments, stimulating an immune response against the prostate cancer.  
 
Case description 
A 71 year-old man with mCRPC presented with Gleason 7 (3+4) prostate 
adenocarcinoma. He underwent radical prostatectomy. He then developed biochemical 
recurrence and underwent salvage radiation therapy to the pelvis and prostate bed. He 
then developed metastatic disease to the lungs with a PSA of 50.36 ng/dL. A chest CT 
scan demonstrated a right lower lobe pulmonary nodule and fine needle aspiration was 
compatible with prostate adenocarcinoma. He was started on androgen deprivation 
therapy with leuprolide for approximately one year before having a rising PSA level. 
Patient was started on bicalutamide but followed with a subsequent demonstration of 
disease progression with enlarged mediastinal and supraclavicular lymph nodes and 
elevation of his PSA to 4.371 ng/dL. The patient received sipuleucel-T. He responded 
remarkably well with normalization of PSA to 0.418 ng/dL (Figure 1) and scans 
demonstrated complete response of his disease by RECIST criteria with a stable 
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superior mediastinal lymph node, reduction in left supraclavicular lymph node, and no 
other evidence of metastatic disease on CT-imaging and nuclear bone scan. Whole 
genome sequencing was done on the patient’s disease to explore potential future 
treatment options. Whole genome sequencing demonstrated that the tumor was MSI-H 
in addition to having a high mutational burden. Patient has been followed since 2014 
and continues to be followed, currently on leuprolide and enzalutamide.  
  
Discussion 
There is limited information on dMMR prostate cancer and its response to sipuleucel-T 
immunotherapy. Patients with dMMR/MSI-H showed significant response to immune 
checkpoint inhibitors and the FDA granted approval of pembrolizumab in all cancer that 
are MSI-H. However, there is no data about the response to cell-based immunotherapy 
such as sipuleucel-T in patients with dMMR/MSI-H. 
 
An interesting observation in this patient is his complete response to sipuleucel-T and 
whether this related to MSI-H status. To the best of our knowledge, this is the first case 
of a complete response to sipuleucel-T in a known dMMR metastatic castrate-resistant 
prostate cancer. Whole genome sequencing may play a role in selecting appropriate 
prostate cancer patients for sipuleucel-T. Ultimately, more research needs to be 
conducted in order to better understand the response of sipuleucel-T in MSI-H/dMMR 
prostate cancers. 
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